CLINICAL TRIAL / NCT04857372

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

  • Interventional
  • Recruiting
  • NCT04857372

An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors

The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.